Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro. The NEPTUNUS pivotal trials achieved the primary endpoint of improving disease activity measured by reducing EULAR Sjögren's syndrome disease activity index (ESSDAI), a multi-dimensional disease activity measurement compared to placebo. In March this year, the U.S. Food and Drug Administration granted Fast Track designation to Johnson & Johns ...